sclc239860_S81.txt
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.570
- G2M_CHECKPOINT+0.550
- PROTEIN_SECRETION+0.460
- MITOTIC_SPINDLE+0.450
- PI3K_AKT_MTOR_SIGNALING+0.410
- MYC_TARGETS_V1+0.370
- DNA_REPAIR+0.330
- MTORC1_SIGNALING+0.320
- OXIDATIVE_PHOSPHORYLATION+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.220
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- ANGIOGENESIS-0.360
- COAGULATION-0.360
- NOTCH_SIGNALING-0.360
- CHOLESTEROL_HOMEOSTASIS-0.350
- MYOGENESIS-0.350
- KRAS_SIGNALING_DN-0.340
- KRAS_SIGNALING_UP-0.310
- INFLAMMATORY_RESPONSE-0.300
- WNT_BETA_CATENIN_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 57ab4aef-e740-4494-b0b5-3b008f9d446f | — | — | 0.867 |
| 2 | BS_HF3RNN2T | Med | Medulloblastoma | 0.843 |
| 3 | TCGA-DK-A3X2-01A-11R-A22U-07 | — | — | 0.837 |
| 4 | BS_7G42J2SK | EPN | Supratentorial EPN | 0.837 |
| 5 | BS_4CP4T22V | Med | Medulloblastoma | 0.832 |
| 6 | SRR1797288 | — | cohortSC | 0.830 |
| 7 | MDT-AP-3042 | Med | Medulloblastoma | 0.822 |
| 8 | TCGA-A2-A0YG-01A-21R-A109-07 | — | C | 0.822 |
| 9 | TCGA-44-7669-01A-21R-2066-07 | — | cohortA3 | 0.821 |
| 10 | BS_A0DYVX9J | high-grade glioma | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.550 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.460 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.450 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.330 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.110 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.080 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.080 | Idelalisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |